Management of Hypopituitarism
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Hypopituitarism includes all clinical conditions that result in partial or complete failure of the anterior and posterior lobe of the pituitary gland’s ability to secrete hormones. The aim of management is usually to replace the target-hormone of hypothalamo-pituitary-endocrine gland axis with the exceptions of secondary hypogonadism when fertility is required, and growth hormone deficiency (GHD), and to safely minimise both symptoms and clinical signs. Adrenocorticotropic hormone deficiency replacement is best performed with the immediate-release oral glucocorticoid hydrocortisone (HC) in 2–3 divided doses. However, novel once-daily modified-release HC targets a more physiological exposure of glucocorticoids. GHD is treated currently with daily subcutaneous GH, but current research is focusing on the development of once-weekly administration of recombinant GH. Hypogonadism is targeted with testosterone replacement in men and on estrogen replacement therapy in women; when fertility is wanted, replacement targets secondary or tertiary levels of hormonal settings. Thyroid-stimulating hormone replacement therapy follows the rules of primary thyroid gland failure with L-thyroxine replacement. Central diabetes insipidus is nowadays replaced by desmopressin. Certain clinical scenarios may have to be promptly managed to avoid short-term or long-term sequelae such as pregnancy in patients with hypopituitarism, pituitary apoplexy, adrenal crisis, and pituitary metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314 · cited 3×
“Abbreviations AC adrenal crisis; ACTH adrenocorticotropic hormone; ADH antidiuretic hormone; AE adverse event; AGHD adults with growth hormone deficiency; AI adrenal insufficiency; AVP arginine vasopressin; BSA body surface area; BW body weight; CBG corticosteroid-binding globulin; CDI central diabetes insipidus; CSHI…”
BackgroundJonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 2×
“6 μg/kg/d [80,81], with dose adjustments affected by age, weight, co-morbidities and physical activity, since TSH is not available as a marker of L-T4 replacement.”
BackgroundBornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 3×
“The last dose should be taken in at least 6 h away from bedtime to avoid sleep disorders or metabolic side-effects [8].”
BackgroundTestosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736 · cited 4×
“Its disadvantage is that it has to be injected in a large volume of 4 mL IM, and coughing episodes have been reported after injection in a small proportion of patients [10].”
BackgroundInfluentialMolitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · cited 11×
“Single or multiple pituitary hormone deficiency [1,7]”
BackgroundMethodInfluentialTreatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884 · cited 1×
“Subcutaneous implants inserted on a 6-month basis may show tachyphylaxis and are difficult to reverse [11].”
BackgroundArlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency
Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411401 · Cited by 644
Classical pituitary apoplexy: clinical features, management and outcome
Randeva, H. S., Schoebel, J., Byrne, J., Esiri, M., Adams, C. B. T., & Wass, J. A. H. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00754.x · Cited by 576 · cited 1×
“Retrospective studies did not find differences in the endocrine outcome between the surgical and conservative approaches [22,93,95].”
ResultThe Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548 · cited 1×
“This circadian rhythm parallels the activity of a primary circadian clock sited in the suprachiasmatic nucleus of the hypothalamus, this synchronising secondary circadian rhythms in other brain areas and in peripheral centers such as the adrenals, and indeed in all cells [28].”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 1×
“This latter fact, along with the fact that the physiological daily production of cortisol may be lower than previously believed [30], can readily result in overtreatment of patients with AI unless great care is taken.”
BackgroundAndrogen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2260 · Cited by 363
Modified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322
A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus
Fenske, W., Refardt, J., Chifu, I., Schnyder, I., Winzeler, B., Drummond, J., Ribeiro-Oliveira, A., Drescher, T., Bilz, S., Vogt, D. R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803760 · Cited by 310
Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases
Sibal, L., Ball, S. G., Connolly, V., James, R. A., Kane, P., Kelly, W. F., Kendall-Taylor, P., Mathias, D., Perros, P., Quinton, R., et al. (2004) · Pituitary · doi:10.1007/s11102-005-1050-3 · Cited by 309
Hahner, S., Loeffler, M., Fassnacht, M., Weismann, D., Koschker, A.-C., Quinkler, M., Decker, O., Arlt, W., & Allolio, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0685 · Cited by 282
Acute management of pituitary apoplexy–surgery or conservative management?
Ayuk, J., McGregor, E. J., Mitchell, R. D., & Gittoes, N. J. L. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02162.x · Cited by 236 · cited 14×
“All patients with PitAp should have ophthalmological and hormonal evaluation in the immediate post-operative or post-acute period and at 4–8 weeks and following the episode, and annually thereafter [91].”
BackgroundInfluentialIsidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Burman, P., Mattsson, A. F., Johannsson, G., Höybye, C., Holmer, H., Dahlqvist, P., Berinder, K., Engström, B. E., Ekman, B., Erfurth, E. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4059 · Cited by 184 · cited 1×
“Finally, pituitary apoplexy (PitAp) or adrenal crisis (AC) are characteristically life-threatening clinical entities [5,6].”
BackgroundConservative management of pituitary apoplexy: a prospective study.
Maccagnan, P., Macedo, C. L., Kayath, M. J., Nogueira, R. G., & Abucham, J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608278 · Cited by 183
Johannsson, G., Burman, P., Wirén, L., Engström, B. E., Nilsson, A. G., Ottosson, M., Jonsson, B., Bengtsson, B.-Å., & Karlsson, F. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8494 · Cited by 175
Appelman-Dijkstra, N. M., Kokshoorn, N. E., Dekkers, O. M., Neelis, K. J., Biermasz, N. R., Romijn, J. A., Smit, J. W. A., & Pereira, A. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0306 · Cited by 162 · cited 1×
“Pituitary adenoma (Functioning and non-functioning) Craniopharyngioma Meningioma Cysts (Rathke’s cleft, arachnoid, epidermoid, dermoid) Germinoma Glioma Astrocytoma Ganglioneuroma Paraganglioma Teratoma Chordoma/Chondrosarcoma Pituicytoma Ependymoma Pituitary carcinoma Metastases Infiltrative/Inflammatory/Immunologica…”
BackgroundAchilli, C., Pundir, J., Ramanathan, P., Sabatini, L., Hamoda, H., & Panay, N. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.028 · Cited by 148 · cited 7×
“In pre-menopausal women with SHG, hormonal replacement therapy (HRT) as oral oestrogen (unopposed oestrogens only for women who have undergone hysterectomy), or combined oestrogen and progestogen therapy (women with an intact uterus to prevent endometrial hyperplasia) is recommended, assuming that no contraindications…”
BackgroundInfluentialAlkatib, A. A., Cosma, M., Elamin, M. B., Erickson, D., Swiglo, B. A., Erwin, P. J., & Montori, V. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0672 · Cited by 147 · cited 12×
“The use of a continuous subcutaneous HC infusion (CSHI) has been reported in patients with PAI, demonstrating a more physiological cortisol circadian rhythm, a normalisation of morning ACTH and restoration of nocturnal serum cortisol levels, along with a better QoL profile compared to conventional HC doses [1,49].”
ResultInfluentialFrench Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Alexopoulou, O., Beguin, C., De Nayer, P., & Maiter, D. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500001 · Cited by 135
Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy
ARAFAH, B. M., HARRINGTON, J. F., MADHOUN, Z. T., & SELMAN, W. R. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-323 · Cited by 134 · cited 2×
“GHD represents the most common endocrine deficit, while GCs are replaced in 60–80%, thyroid hormone in 50–60%, DDAVP in 10–25% of patients and testosterone in 60–80% of men [24,93,95,96].”
BackgroundResultVerma, S., VanRyzin, C., Sinaii, N., Kim, M. S., Nieman, L. K., Ravindran, S., Calis, K. A., Arlt, W., Ross, R. J., & Merke, D. P. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03636.x · Cited by 126
Whitaker, M. J., Debono, M., Huatan, H., Merke, D. P., Arlt, W., & Ross, R. J. (2014) · Clinical Endocrinology · doi:10.1111/cen.12316 · Cited by 121
Slawik, M., Klawitter, B., Meiser, E., Schories, M., Zwermann, O., Borm, K., Peper, M., Lubrich, B., Hug, M. J., Nauck, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0297 · Cited by 113
Lebbe, M., & Arlt, W. (2013) · Clinical Endocrinology · doi:10.1111/cen.12097 · Cited by 86 · cited 1×
“An increase by 20–40% in the dosing of HC maybe needed during the third trimester since free cortisol normally increases during this period [7,51,88].”
BackgroundBehan, L. A., Sherlock, M., Moyles, P., Renshaw, O., Thompson, C. J. T., Orr, C., Holte, K., Salehmohamed, M. R., Glynn, N., Tormey, W., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0719 · Cited by 75
Ragnarsson, O., Mattsson, A. F., Monson, J. P., Filipsson Nyström, H., Åkerblad, A.-C., Kołtowska-Häggström, M., & Johannsson, G. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0397 · Cited by 46 · cited 12×
“The use of a continuous subcutaneous HC infusion (CSHI) has been reported in patients with PAI, demonstrating a more physiological cortisol circadian rhythm, a normalisation of morning ACTH and restoration of nocturnal serum cortisol levels, along with a better QoL profile compared to conventional HC doses [1,49].”
BackgroundInfluentialDiagnosis and management of diabetes insipidus during pregnancy
Durr, J. A., & Lindheimer, M. D. (1996) · Endocrine Practice · doi:10.4158/ep.2.5.353 · Cited by 42 · cited 2×
“In pregnant women with DI, it is suggested to continue DDAVP administration during pregnancy, adjusting the dose if required, since the different water-balance which is established by a decreased threshold for AVP release and thirst mechanism results in decreased serum sodium and osmolality [89].”
BackgroundPorter, J., Withe, M., & Ross, R. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1455496 · Cited by 26 · cited 1×
“5 mg, 1 mg, 2 mg and 5 mg [48] (Table 2).”
van Varsseveld, N. C., van Bunderen, C. C., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1764 · Cited by 26 · cited 1×
“However, high doses of replacement may result to insulin resistance and/or new-onset diabetes [53].”
BackgroundMeasurement of salivary cortisone to assess the adequacy of hydrocortisone replacement
Raff, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1228 · Cited by 19 · cited 1×
“salivary cortisol day curve may prove to represent a more reliable and convenient way of titrating doses and timing in some cases [1,36,37].”
Background
Cited by
A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus
Fenske, W., Refardt, J., Chifu, I., Schnyder, I., Winzeler, B., Drummond, J., Ribeiro-Oliveira, A., Drescher, T., Bilz, S., Vogt, D. R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803760 · Cited by 310
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Kayadjanian, N., Hsu, E. A., Wood, A. M., & Carson, D. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad488 · Cited by 28
Metadata
- Authors
- Alexandraki, K., & Grossman, A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-12-05
- Volume
- 8
- Issue
- 12
- Pages
- 2153
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2993500582
- Cited by
- 62
- References
- 38
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.